COMMENTARY

Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest

By Takashi Ohama February 9, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

To read the full story

CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019

COMMENTARY

A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
March 9, 2026
G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste

By Ken Yoshino

Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…